Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Following the current path, stroke cases will increase by 28.9% between 2003 and 2023 (estimates do not include strokes among the institutionalized population). If an alternative path is taken, there…  
  • “Although high cholesterol was recognized as a key risk factor for cardiovascular disease in the 1970s, there were no good ways to reduce it. The best drug available was…  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • Use of antihypertensive therapies avoided an estimated $10.7 billion in 2002 direct medical costs as a result of fewer strokes. They also avoided an estimated $5.8 billion in 2002…  
  • 277 medicines are currently in development to treat or prevent heart disease and stroke.